MarketWatch June 9, 2021
Dyadic International (NASDAQ: DYAI): A Unique Approach to World Vaccination (DYAI, AZN, MRNA, NVAX, PFE, JNJ, BNTX)

MarketWatch June 2, 2021
The Vaccine Investment Hypothesis, and What’s Next (AZN, JNJ, DYAI, BNTX)

MarketWatch May 26, 2021
Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA) May 20, 2021
Could Dyadic International (DYAI) be a Dark Horse Vaccine MVP

Wall Street May 12, 2021
DYAI’s C1 Technology May be Key in the Race to Vaccine-Induced Herd Immunity

Elsevier Biologicals April 2021
Can a fungal platform be faster and cheaper than other platforms, enabling many cheaper and quicker therapeutics? Joris Vandeputte responded that the ZAPI experience shows that the fungal C1 system is a high-performance system, which can produce high quantities of apparently excellent antigens, in the appropriate conformation, and well glycosylated, which has been confirmed in animal models. So, this is one of the platforms that should be further explored in the near future.

MarketWatch April 28, 2021
Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYAI)

Journal Transcript April 20, 2021
DYAI in Focus: Upstart Vaccine Maker Says has Faster Way to Vaccinate the World (AZN, MRNA, NVAX, PFE, JNJ, BNTX) April 9, 2021
Is Dyadic International Inc. (NASDAQ: DYAI) the Key to the Next Wave of Vaccinations? (NASDAQ: AZN) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: NVAX)

MarketWatch April 1, 2021
How Dyadic International Inc (NASDAQ: DYAI) Fits into the Vaccine 2.0 Gold Rush (NASDAQ: BNTX) (NYSE: JNJ) (NASDAQ: MRNA) (NYSE: PFE) March 30, 2021
Is Dyadic International Inc. (NASDAQ: DYAI) the Key to Scaling Up Global Access to a Viable Covid-19 Vaccine?  (NASDAQ: NVAX) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: AZN)

Innovative Medicines Initiative March 24, 2021
A recipe for the next disaster: a new, pan-virus methodology for ramping up vaccine production
ZAPI have put in place a new pan-virus methodology for ramping up the production of new vaccines in the next crisis March 23, 2021
Covid-19 Pandemic Still Fueling Need for Increased Supplies & New Technology in PPE Markets

Benzinga – Silvia Munoz Campo, December 10, 2020
Dyadic Biotechnology Is On A Quest To Find A Solution For COVID-19

Horizon, the EU Research & Innovation Magazine, April 7, 2020
Studying animal coronavirus defences is opening route to human treatments

Innovative Medicines Initiative, March 30, 2020
ZAPI is laying the groundwork for the response to zoonotic disease outbreaks like COVID-19

BioProcess International, August 16, 2019
Dyadic: Deals stack up as industry looks to ‘game-changing’ expression system July 2, 2019
FDA should improve incentives to lower drug costs, says Dyadic CEO

Tailwinds Research Group February 21, 2019
DYAI Looking Increasingly Compelling

NBC News January 31, 2019
The shutdown is over – but not the pain for small businesses

Manufacturing Chemist, January 30, 2019
Is the Production of Biologic Drugs Ready for an Overhaul?

The Washington Post, January 23, 2019
Stuck in shutdown limbo, companies put IPOs on hold

DGIwire January 11, 2019
Looking Beyond Mammals to Microbes for Tomorrow’s Drugs

DGIwire December 3, 2018
Is a Fungus Among Us the Key to Tomorrow’s Biologic Drugs?

DGIwire November 26, 2018
Building Better Biologics: A Challenge for the Biopharma Industry

Science, November 16, 2018
Protein expression, revisited

R&D Magazine / Pharmaceutical Processing, November 5, 2018
Fungal Strain Technology Could Disrupt Bio-Manufacturing Industry

BioPharm International, November 1, 2018
Media Requirements for Different Cell Sources, October 5, 2018
Biologic Drugs Challenge the Biopharma Industry

Yahoo Finance, October 4, 2018
Undervalued Stocks You Can’t Afford to Miss

Biocompare, September 27, 2018
CHO Cells: Beginning of the End or End of the Beginning?

Pharmaceutical Manufacturing, September 25, 2018
Ditching the Model T for a Faster Ride, September 24, 2018
CHO cells the 1900s model car in a 2020 Tesla world, says Dyadic

ContractPHARMA, September 18, 2018
Dyadic, Sanofi in Research Collaboration

BioProcess International, September 12, 2018
Sanofi deal shows demand for CHO alternatives, says Dyadic, September 20, 2018
Sanofi Partners with Dyadic to Research Fungus-Based Expression Platform August 2, 2018
The Challenge of Building Better Biologic Drugs

BioSpace, August 7, 2018
From “Jeans to Genes”: Mark Emalfarb Thinks He Can Revolutionize Biopharma Manufacturing

BioPharm International, August 1, 2018
“The Search for Next-Gen Expression Systems”, July 2, 2018
“The Search for Next-Gen Expression Systems“

BioProcess International, June 5, 2018
Dyadic to Develop Biosimilars Using CHO-Challenging Expression System April 4, 2018
Dyadic confident Big Biopharma will move away from CHO cell reliance February 21, 2018
“There is a new kid on the block to rival E. Coli, CHO and yeast” says Dyadic International as it collaborates to widen the use of its C1 expression technology, February 21, 2018
Dyadic enters R&D deal for its fungus-based expression system

Tailwinds Research Group LLC  October 9, 2017
Dyadic… Understanding the Value Proposition of C1 and the Stock August 25, 2017
CHO platforms unsustainable for biopharma’s future, says Dyadic

Tailwinds Research Group LLC August 23, 2017
Can Dyadic Reduce the Costs of Biologics?

Bloomberg News, May 9, 2014
Noel, Andrew. “BASF’s Enzyme-Research Overload Raises Prospects for Dyadic Work”

Biofuels International, May/June 2014
Zeman, Nicholas. “The Final Push

The Palm Beach Post May 20, 2013
Ostrowski, Jeff.  “Jupiter-based Dyadic makes $6 million deal with BASF”

Biomass Magazine May 16, 2013
Voegele, Erin.  “BASF announces agreements with Genomatica, Dyadic”

BioFuels Digest May 16, 2013
Lane, Jim.  “Fearsome Foursome:  BASF, with 3 new deals, heads for the big league in industrial enzymes”

BioBased Digest May 16, 2013
Saidak, Tom.  “BASF comments on its enzyme technology footprint”

South Florida Business Journal May 16, 2013
Bandell, Brian.  “Dyadic shares rise after research deal with BASF”

Genetic Engineering & Biotechnology News May 15, 2013
“BASF Using Dyadic Technology for New Enzymes in $6M+ Deal”

Bloomberg May 15, 2013
Noel, Andrew.  “BASF Reaches Enzyme-Platform Licensing Accord with Dyadic”

Bloomberg BusinessWeek May 15, 2013
Noel, Andrew.  “BASF Reaches Enzyme-Platform Licensing Accord with Dyadic”

SEKAB Media September 2012
Nilsson, Kristina.  “Effective Enzymes for the Degradation of Cellulose — SEKAB and Dyadic in Cooperation on Verification”

The Palm Beach Post May 2012
Roach, Emily. “Jupiter Biotech Firm Touts Enzyme That Makes Thinner, Stronger Paper.”

Renewable Energy Magazine August 2011
Emalfarb, Mark. “Green Sugars, the New Oil?”

The Palm Beach Post August 2010
Ostrowski, Jeff. “Dyadic Poised for Key Role in Biofuel Movement.” November 2009
Bradshaw, Kit. “Future is Sweet for Jupiter CEO.”

Renewable Energy Magazine October 2009
“Interview: Mark Emalfarb, CEO of Dyadic International.”

South Florida Business Journal May 2009
Bandell, Brian. “Dyadic CEO Makes a Comeback.”

Business Week December 2006
“Put a Termite In Your Tank.”

Entrepreneur December 2006
“Good Genes.”

Chicago Tribune October 13, 2006
Oneal, Michael. “Scientists Seek Cheap, Plentiful Energy Alternatives.”

BioPharm International May 1, 2006
Burlingame, Richard. “Maximizing Protein Expression in Filamentous Fungi.”